- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
- Interventions
- FHD-286, Low Dose Cytarabine, Decitabine
- Drug
- Lead sponsor
- Foghorn Therapeutics Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Leukemia
- Interventions
- BMS-936564, Cytarabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orlando, Florida • Louisville, Kentucky + 6 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986178, Nivolumab, Ipilimumab, Tetanus vaccine, DPV-001 vaccine, Cyclophosphamide
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
- Interventions
- Vixarelimab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
- Interventions
- Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan
- Biological · Drug
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Injury in the Home
- Interventions
- Injury Intervention Group
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 650 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Osteosarcoma
- Interventions
- Losartan, Sunitinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1995
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Research Triangle Park, North Carolina + 1 more
- Conditions
- Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Interventions
- [18F]FluorThanatrace, PET/CT imaging sessions
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Interventions
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
- Conditions
- Brain Neoplasms
- Interventions
- [18F] FLT
- Drug
- Lead sponsor
- Frederick Daniel Grant
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Carcinoma
- Interventions
- Educational Intervention, Genetic Testing, Survey Administration, ProGene Artificial Intelligence (AI) Platform, Interviews
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- San Francisco, California
- Conditions
- Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
- Interventions
- DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), Provider dashboard
- Device · Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
- Interventions
- Metformin, Questionnaires
- Drug · Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease
- Interventions
- Abbott SJM Rigid Saddle Ring, Abbott SJM Séguin Ring, Abbott SJM Tailor Ring, Abbott SJM Tailor Band
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Madison, Wisconsin
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- tetomilast, placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Torrance, California • Kissimmee, Florida + 12 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Atezolizumab, Bevacizumab, Tiragolumab, Tobemstomig
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 2 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
- Drug · Combination Product · Procedure + 2 more
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,937 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 19 more
- Conditions
- Solid Tumors
- Interventions
- PLX3397, Paclitaxel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 5 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Interventions
- elzovantinib (TPX-0022)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • Orange, California • Denver, Colorado + 8 more
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Various Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, Daratumumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more